This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, B. C. Articles by Haffty, B. G. Search for Related Content PubMed PubMed Citation Articles by Turner, B. C. Articles by Haffty, B. G. Social Bookmarking                            What's this?

BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations

From the Departments of Therapeutic Radiology, Genetics, and Surgery, Yale University School of Medicine, New Haven, CT; Myriad Genetics, Inc, Salt Lake City, UT; and Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA.

Address reprint requests to Bruce G. Haffty, MD, Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520-8040; email bruce.haffty{at}yale.edu

PURPOSE: Breast cancer patients treated conservatively with lumpectomy and radiation therapy (LRT) have an estimated lifetime risk of local relapse (ipsilateral breast tumor recurrence [IBTR]) of 10% to 15%. For breast cancer patients carrying BRCA1 or BRCA2 (BRCA1/2) mutations, the outcome of treatment with LRT with respect to IBTR has not been determined. In this study, we estimate the frequency of BRCA1/2 mutations in a study of breast cancer patients with IBTR treated with LRT.

PATIENTS AND METHODS: Between 1973 and 1994, there were 52 breast cancer patients treated with LRT who developed an IBTR within the prior irradiated breast and who were willing to participate in the current study. From our database, we also identified 52 control breast cancer patients treated with LRT without IBTR. The control patients were individually matched to the index cases with respect to multiple clinical and pathologic parameters. Lymphocyte DNA specimens from all 52 locally recurrent patients and 15 of the matched control patients under age 40 were used as templates for polymerase chain reaction amplification and dye-primer sequencing of exons 2 to 24 of BRCA1, exons 2 to 27 of BRCA2, and flanking intron sequences.

RESULTS: After LRT, eight (15%) of 52 breast cancer patients had IBTR with deleterious BRCA1/2 mutations. By age, there were six (40%) of 15 patients with IBTR under age 40 with BRCA1/2 mutations, one (9.0%) of 11 between ages 40 and 49, and one (3.8%) of 26 older than age 49. In comparison to the six (40%) of 15 of patients under age 40 with IBTR found to have BRCA1/2 mutations, only one (6.6%) of 15 matched control patients without IBTR and had a BRCA1/2 mutation (P = .03). The median time to IBTR for patients with BRCA1/2 mutations was 7.8 years compared with 4.7 years for patients without BRCA1/2 mutations (P = .03). By clinical and histologic criteria, these relapses represented second primary tumors developing in the conservatively treated breast. All patients with BRCA1/2 mutations and IBTR underwent successful surgical salvage mastectomy at the time of IBTR and remain alive without evidence of local or systemic progression of disease.

CONCLUSION: In this study, we found an elevated frequency of deleterious BRCA1/2 mutations in breast cancer patients treated with LRT who developed late IBTR. The relatively long time to IBTR, as well as the histologic and clinical criteria, suggests that these recurrent cancers actually represent new primary breast cancers. Early onset breast cancer patients experiencing IBTR have a disproportionately high frequency of deleterious BRCA1/2 mutations. This information may be helpful in guiding management in BRCA1 or BRCA2 patients considering breast-conserving therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. J. Pierce, A. M. Levin, T. R. Rebbeck, M. A. Ben-David, E. Friedman, L. J. Solin, E. E. Harris, D. K. Gaffney, B. G. Haffty, L. A. Dawson, et al. Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2437 - 2443. [Abstract] [Full Text] [PDF]

				S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]

				J. Rogozinska-Szczepka, B. Utracka-Hutka, E. Grzybowska, B. Maka, E. Nowicka, A. Smok-Ragankiewicz, H. Zientek, J. Steffen, and A. Wojciechowska-Lacka BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients Ann. Onc., September 1, 2004; 15(9): 1373 - 1376. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, S. M. McCaffrey, R. Nedelcu, D. J. MacDonald, K. R. Blazer, and C. A. Cullinane Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis Arch Surg, December 1, 2003; 138(12): 1323 - 1328. [Abstract] [Full Text] [PDF]

				H. T. Lynch, C. L. Snyder, J. F. Lynch, B. D. Riley, and W. S. Rubinstein Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist J. Clin. Oncol., February 15, 2003; 21(4): 740 - 753. [Abstract] [Full Text] [PDF]

				N. Hoogerbrugge, P. Bult, L.M. de Widt-Levert, L.V. Beex, L.A. Kiemeney, M.J.L. Ligtenberg, L.F. Massuger, C. Boetes, P. Manders, and H.G. Brunner High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer J. Clin. Oncol., January 1, 2003; 21(1): 41 - 45. [Abstract] [Full Text] [PDF]

				T. Whelan, J. Julian, M. Levine, R. Arriagada, I. Kunkler, H. Bartelink, J.-C. Horiot, and P. Poortmans Radiotherapy for Breast Cancer N. Engl. J. Med., March 14, 2002; 346(11): 862 - 864. [Full Text] [PDF]

				J. Chang, S. G. Hilsenbeck, J. H. Sng, J. Wong, and G. C. Ragu Pathological Features and BRCA1 Mutation Screening in Premenopausal Breast Cancer Patients Clin. Cancer Res., June 1, 2001; 7(6): 1739 - 1742. [Abstract] [Full Text] [PDF]

				D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus, C. Gautier, M. Gauthier-Villars, E. Bourstyn, K. B. Clough, H. Magdelenat, P. Pouillart, A. Vincent-Salomon, et al. Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations J. Clin. Oncol., December 15, 2000; 18(24): 4053 - 4059. [Abstract] [Full Text] [PDF]

				L. J. Pierce, M. Strawderman, S. A. Narod, I. Oliviotto, A. Eisen, L. Dawson, D. Gaffney, L. J. Solin, A. Nixon, J. Garber, et al. Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations J. Clin. Oncol., October 19, 2000; 18(19): 3360 - 3369. [Abstract] [Full Text] [PDF]

				S. C. Formenti, S. Preston-Martin, and B. G. Haffty BRCA1/2 Germline Mutations: A Marker for Radioresistance or Radiosensitivity? J. Clin. Oncol., March 1, 2000; 18(5): 1159 - 1159. [Full Text] [PDF]

				M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy, A. Heerdt, P. Borgen, B. McCormick, C. Hudis, L. Norton, et al. Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations J Natl Cancer Inst, December 15, 1999; 91(24): 2112 - 2117. [Abstract] [Full Text] [PDF]

				B. C. Turner, P. M. Glazer, B. G. Haffty, and S. Hellman BRCA1/BRCA2 in Breast-Conserving Therapy J. Clin. Oncol., November 1, 1999; 17(11): 3689 - 3689. [Full Text] [PDF]

				S. Hellman The Key and the Lamppost J. Clin. Oncol., October 1, 1999; 17(10): 3007 - 3008. [Full Text] [PDF]